Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa
NCT02421172Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of CJM112 in hidradenitis suppurativa (HS), sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
CJM112
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT02421172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421172.